SAT-330 Preclinical Screen of Patient CRPC Tumors Shows Sensitivity to Bromodomain Inhibitors Includes AR-null and Neuroendocrine Disease

Castration-resistant prostate cancer (CRPC) remains a lethal disease despite the introduction of second generation androgen receptor (AR) directed therapies. Resistance to AR directed therapies, such as abiraterone and enzalutamide, emerges through diverse alterations in the AR pathway or transition...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Endocr Soc
Main Authors: Risbridger, Gail, Ashikari, Daisaku, Lawrence, Mitchell, Obinata, Daisuke, Wang, Hong, Sandhu, Shahneen, Azad, Arun, Taylor, Renea
Formato: Artigo
Idioma:Inglês
Publicado em: Endocrine Society 2019
Assuntos:
Tumor Biology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6551945/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SAT-330
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados